An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Doptelet

Chemical Nameavatrombopag
Dosage FormTablet (oral; 20 mg)
Drug ClassReceptor agonists
SystemBlood
CompanyAkaRx
Approval Year2018

Indication

  • Doptelet is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
  • Doptelet is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Last updated on 2/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Doptelet (avatrombopag) Prescribing Information2019AkaRx
Document TitleYearSource
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure.2020NICE
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.2020NIHR
Document TitleYearSource
Efficacy and safety of Avatrombopag in patients with Thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials.2019Frontiers in Pharmacology
Therapeutic options for adult patients with previously treated immune thrombocytopenia – a systematic review and network meta-analysis.2019Hematology